Bleeding control improves after switching to emicizumab: Real‐world experience of 177 children in the PedNet registry

Documents similaires

• Differences Between Sweden and Greece in Joint Outcomes Assessed by Ultrasound in Adolescents With Severe Haemophilia on Prophylaxis: Data From the PedNet Registry
  par: Aikaterini Michalopoulou, et autres
  Publié: (2025)
• Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group
  par: Marloes de Kovel, et autres
  Publié: (2025)
• Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real‐world evidence
  par: Gili Kenet, et autres
  Publié: (2024)
• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  par: Christian Pfrepper, et autres
  Publié: (2024)
• The importance and evolution of bleeding disorder registries
  par: Huyen Tran, et autres
  Publié: (2024)